Pregnancy RSV vaccine slashes newborn hospital admissions by over 80%

A vaccine administered during pregnancy is dramatically reducing hospital admissions among newborns with respiratory syncytial virus (RSV), with UK health officials reporting a reduction of more than 80 per cent. The jab, provided to pregnant women from 28 weeks of gestation since 2024, protects babies from birth by enhancing maternal immunity and passing protection through the placenta. A major new study analysing nearly 300,000 births across England between September 2024 and March 2025 has demonstrated the vaccine’s “excellent protection” during the timeframe when infants are particularly susceptible to the virus. RSV affects roughly half of all newborns and remains one of the primary reasons of hospital admission in babies under one year old, with more than 20,000 serious cases recorded annually across the UK.

How the immunisation protects vulnerable infants

RSV, or respiratory syncytial virus, is a frequent respiratory infection that affects roughly half of all newborns in their first few months of life. The virus can vary from causing mild cold-like symptoms to triggering severe chest infections that leave babies struggling to breathe and feed. In the most severe cases, the lung inflammation becomes life-threatening, with small numbers of infants dying from the infection each year. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, emphasises the distressing nature of severe RSV infections: “In babies with severe infections you can see their chest and lungs working hard, as they attempt to draw enough oxygen in. This is extremely frightening as a parent, frightening for good reason.”

The pregnancy vaccine functions by activating the mother’s body’s defences to produce defence proteins, which are then passed to the developing baby through the placenta. This maternal immunity offers newborns with instant defence from the moment of birth, exactly when they are highly susceptible to RSV. The latest research demonstrates that protection reaches nearly 85 per cent when the vaccine is given at least four weeks before delivery. Even briefer gaps between vaccination and birth can still provide substantial defence, with evidence suggesting that a two-week gap is adequate to shield babies delivered prematurely. Dr Watson advises pregnant women to have the vaccine on schedule, whilst observing that protection can still occur even if given later in the third trimester.

• Nearly 85 per cent coverage when immunised 4 weeks before birth
• Antibodies from the mother passed through placenta protect newborns from birth
• Protection achievable with two-week gap before early delivery
• Vaccination in the third trimester still provides significant infant protection

Strong evidence from the latest research

The performance of the RSV vaccine administered during pregnancy has been confirmed through a extensive research programme undertaken in England, reviewing data from close to 300,000 babies born between September 2024 and March 2025. This constitutes approximately 90% of all births during that six-month period, providing strong and reliable information of the vaccine’s actual performance. The study’s findings have been supported by the UK Health Security Agency as showing robust protection for newborns during their most vulnerable early months. The breadth of this investigation gives healthcare professionals and prospective parents with trust in the vaccine’s demonstrated effectiveness across different groups and contexts.

The results reveal a compelling picture of the vaccine’s protective effectiveness. More than 4,500 babies were hospitalised with RSV during the study period, with the great majority being infants whose mothers had not been given the vaccination. This clear distinction emphasises the vaccine’s critical role in preventing serious illness in newborns. The drop in hospital admissions surpassing 80 per cent represents a significant public health achievement, potentially preventing thousands of infants from experiencing the distressing and potentially serious symptoms associated with severe RSV infection. These findings reinforce the importance of the vaccination programme established in the UK in 2024.

Methodology and scope of study

The research reviewed birth and hospitalisation records from England over a six-month period, capturing data on approximately 90 per cent of all births during this timeframe. By examining nearly 300,000 babies born to both vaccinated and unvaccinated mothers, researchers were able to identify direct comparisons of RSV infection levels and hospital admissions. The sizeable sample and thorough nature of the data collection ensured that findings were statistically robust and representative of the broader population, rather than individual cases or small subgroups.

The study specifically recorded hospital admissions for RSV among infants born to mothers who had received the vaccine at differing periods before delivery. This allowed researchers to identify the least amount of time between vaccination and birth for maximum protection, as well as to determine whether protection continued to be effective with shorter intervals. The methodology measured practical outcomes rather than laboratory-based settings, providing practical evidence of how the vaccine performs when administered across different clinical contexts and patient circumstances throughout the third trimester of pregnancy.

Learning about RSV and its threats

Respiratory syncytial virus, typically known as RSV, is one of the leading causes of hospitalisation in infants aged under twelve months across the United Kingdom. The virus affects approximately half of all newborns during their early months of life, with severity varying dramatically from minor cold-type symptoms to serious, potentially fatal chest infections. Over 20,000 infants require serious hospital treatment for RSV annually in the UK alone, placing enormous strain on children’s wards and newborn care units during busier periods.

The infection triggers inflammation deep within the lungs and airways, making it extremely challenging for affected infants to breathe and feed properly. Parents frequently observe their babies fighting for breath, their chests heaving as they try to pull adequate oxygen into their compromised lungs. Whilst most newborns recover with clinical support, a limited though important proportion perish from respiratory syncytial virus complications yearly, making immunisation programmes a essential public health priority for protecting the most vulnerable and youngest individuals in the population.

• RSV causes inflammation in lungs, causing serious respiratory problems in babies
• Approximately half of newborns contract the virus during their first few months alive
• Symptoms span from mild colds to life-threatening chest infections needing hospital treatment
• Over 20,000 UK babies require serious hospital care for RSV each year
• Small numbers of infants succumb to RSV related complications annually in the UK

Adoption rates and specialist advice

Since the RSV vaccine programme commenced in 2024, health officials have highlighted the significance of pregnant women receiving their jab at the best time for greatest protection. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, has underscored that the timing is essential for ensuring newborns receive the most robust immunity from birth. Whilst the evidence indicates that vaccination at least four weeks before delivery offers approximately 85% protection, experts encourage women to receive their vaccine as early as possible from 28 weeks of pregnancy onwards to maximise the antibodies transferred to their babies via the placenta.

The messaging from health authorities remains clear: pregnant women should prioritise vaccination during their third trimester, even if circumstances mean they cannot get vaccinated at the best timing. Dr Watson has provided reassurance to pregnant women that protection remains still achievable with shorter intervals between vaccination and birth, including even a two-week gap for those delivering slightly early. This adaptable strategy acknowledges the practical demands of pregnancy whilst maintaining strong safeguarding for at-risk infants during their earliest and most vulnerable period when RSV poses the greatest risk of serious illness.

Regional disparities in vaccine uptake

Whilst the RSV vaccine programme has been launched across England, uptake rates and deployment schedules have varied across various areas and NHS trusts. Certain regions have achieved higher vaccination coverage among qualifying expectant mothers, whilst others remain focused to increase awareness and availability of the jab. These geographical variations demonstrate variations in healthcare infrastructure, communication strategies, and local engagement efforts, though the overall statistics demonstrates robust and reliable protection irrespective of geographical location.

• NHS trusts rolling out diverse outreach initiatives to connect with expectant mothers
• Regional disparities in vaccine uptake rates in different parts of England require targeted improvement
• Local healthcare systems modifying schemes to suit community needs and circumstances

Practical implications and parent viewpoints

The vaccine’s impressive effectiveness provides real advantages for families throughout the United Kingdom. With over 20,000 babies hospitalised annually due to RSV before the launch of this safeguarding intervention, the 80% drop in admissions means thousands of infants spared from serious illness. Parents no longer face the upsetting situation of seeing their babies gasping for air or labour to feed, symptoms that characterise serious RSV disease. The vaccine has markedly changed the picture of neonatal breathing health, providing expectant mothers a active means to shield their most at-risk babies during those vital initial period.

For families like that of Malachi, whose serious RSV infection resulted in severe brain damage, the vaccine’s availability carries significant emotional significance. His mother’s promotion of the jab highlights the profound consequences that vaccine-preventable disease can have on young children and their families. Whilst Malachi’s experience comes before the vaccine programme, his story resonates strongly with parents now provided with protection. The knowledge that such significant complications—hospital admission, oxygen dependency, neurological damage—are now mostly preventable has provided considerable reassurance to pregnant women in their final trimester, changing what was once an unavoidable seasonal threat into a manageable health risk.